Baxter International Inc. Soars as it Sells Kidney-Care Business to Carlyle Group for $3.8 Billion
In a major move that has sent shockwaves through the financial market, Baxter International Inc. has announced the sale of its kidney-care business to private-equity giant Carlyle Group Inc. The deal, valued at a staggering $3.8 billion, has investors buzzing with excitement as shares of Baxter International Inc. surged early Tuesday.
The newly formed company, Vantive, is set to revolutionize the healthcare-products industry with its focus on kidney care. With Carlyle Group’s backing, Vantive is poised for rapid growth and success in the market.
This strategic move by Baxter International Inc. is expected to have a significant impact on the company’s future financial performance. Investors are eagerly watching to see how this sale will affect Baxter International Inc.’s bottom line and stock price in the coming months.
In conclusion, this groundbreaking deal between Baxter International Inc. and Carlyle Group Inc. is a game-changer in the healthcare-products industry. Investors should keep a close eye on this development as it unfolds, as it has the potential to shape the future of both companies and the market as a whole.